Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?
Clinical Infectious Diseases · 06.10.2025 · 81 (3) · 570-580
DOI: 10.1093/cid/ciae602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.12.2024. Verfasst von José Luis Piñana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Clínico Universitario of Valencia, Spain. Hauptthemen laut MEDLINE: Community-Acquired Infections, Respiratory Tract Infections, Hematopoietic Stem Cell Transplantation, Survivors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Studies on late community-acquired respiratory virus (CARV) infections in long-term allogeneic hematopoietic stem cell transplantation (allo-HCT) survivors are scarce, creating knowledge gaps on the epidemiology, risk of progression to lower respiratory tract disease (LRTD), and conditions linked to poor outcomes.
Methods
We included consecutive CARV infection episodes occurring up to 6 months after allo-HCT registered in our database from December 2013 to June 2023 at 2 Spanish transplant centers.
Results
Among 426 allo-HCT recipients, 1070 CARV episodes were recorded, 791 (74%) with only upper respiratory tract disease (URTD) and 279 (15%) progressing to LRTD, at a median of 18.6 months post-transplant. The most common CARVs were rhinovirus, respiratory syncytial virus (RSV), and influenza. The LRTD progression rate was 26%, with a 4.9% all-cause mortality rate at 100 days post-CARV detection. Risk factors for LRTD progression included graft-versus-host disease prophylaxis (odds ratio [OR] 3.08), corticosteroid use (0.1 to <30 mg/day: OR 2.44; ≥30 mg/day: OR 5.19), absolute lymphocyte count (ALC) <1 × 10^9/L (OR 1.60), fever at CARV screening (OR 4.27), RSV (OR 2.46), and human metapneumovirus (HMPV) (OR 2.76). Risk factors for 100-day all-cause mortality included human leukocyte antigen (HLA) mismatch (hazard ratio [HR] 2.49); corticosteroid use (0.1 to <30 mg/day: HR 3.87; ≥30 mg/day: HR 5.77); ALC <1 × 10^9/L (HR 2.44); neutropenia <0.5 × 10^9/L (HR 6.74), and age ≥40 years (HR 4.85).
Conclusions
Recipients with profound and prolonged immunosuppression remain at risk for severe CARV infection outcomes late after allo-HCT, necessitating intensive clinical monitoring for respiratory symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Hospital Clínico Universitario of Valencia, Spain.
- INCLIVA, Biomedical Research Institute, Valencia, Spain.
- Biostatistical department of INCLIVA, Biomedical Research Institute, Valencia, Spain.
- Microbiology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Hematology Division, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
ORCID-Profile: José Luis Piñana, Dolores Gómez, Pedro Chorão
Zitieren
APA
Piñana, J. L., Carbonell-Asins, J. A., Gómez, D., Montoro, J., Pérez, A., Hernani, R., Chorão, P., Hernández-Boluda, J. C., Navarro, D., & Solano, C. (2025). Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?. Clinical Infectious Diseases, 81(3), 570-580. https://doi.org/10.1093/cid/ciae602
Vancouver
Piñana JL, Carbonell-Asins JA, Gómez D, Montoro J, Pérez A, Hernani R, et al. Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?. Clinical Infectious Diseases. 2025;81(3):570-580. doi:10.1093/cid/ciae602
BibTeX
@article{Piana2025,
author = {Piñana, José Luis and Carbonell-Asins, Juan A and Gómez, Dolores and Montoro, Juan and Pérez, Ariadna and Hernani, Rafael and Chorão, Pedro and Hernández-Boluda, Juan Carlos and Navarro, David and Solano, Carlos},
title = {Community-Acquired Respiratory Virus Infections: A Threat to Long-Term Survivors After Allogeneic Stem Cell Transplant?},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {3},
pages = {570--580},
doi = {10.1093/cid/ciae602}
}
EUVIMED